Switching versus augmentation: A prospective, naturalistic comparison in depressed, treatment-resistant patients

Journal of Clinical Psychiatry

Volumn 62, Issue 2, 2001, Pages 135-142

  Posternak, M A ^a   Zimmerman, M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RELAPSE; TREATMENT OUTCOME;

EID: 0035098979     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v62n0212     Document Type: Article

References (48)

1. Tricyclic nonresponders: Phenomenology and treatment
2. Discontinuing antidepressant treatment in major depression
3. What next? A review of pharmacologic strategies for treatment resistant depression
4. Treatment-resistant depression: Definition and treatment approaches
5. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression
6. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system
7. Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depression
8. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: Results of a placebo-controlled double-blind study
9. Treatment of imipramine-resistant recurrent depression. 2: An open clinical trial of lithium augmentation
10. Refractory depression: The addition of lithium to fluoxetine or desipramine
11. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine
12. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression
13. Thyroid-hormone enhancement of imipramine in nonretarded depressions
14. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression
15. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
16. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression
17. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
18. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression
19. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression
20. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis
21. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
22. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report
23. Fluoxetine in tricyclic refractory major depressive disorder
24. Trazodone in treatment-resistant depression: An open study
25. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder
26. Venlafaxine for treatment-resistant unipolar depression
27. Efficacy of bupropion in tricyclic-resistant or intolerant patients
28. Fluoxetine efficacy in treatment resistant depression
29. Response to an open trial of a second SRI in major depression
30. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
31. Comparison between zimelidine and desipramine in endogenous depression: A cross-over study
32. Serotonin reuptake inhibition vs norepinephrine reuptake inhibition: A double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives
33. A double-blind comparison of zimelidine and desipramine in endogenous depression
34. Treatment strategy in depression, I: Non-tricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine
35. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients: A cross-over study
36. The short- and long-term efficacy of paroxetine HCl, B: Data from a double-blind crossover study and from a year-long trial vs imipramine and placebo
37. Fluvoxamine in the treatment of tricyclic-resistant depression
38. Treatment of antidepressant nonresponders: Augmentation or switch?
39. Psychiatric diagnosis in clinical practice: Is comorbidity being missed?
40. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant
41. A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment
42. Are antidepressant trials too short? A case report
43. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine
44. What constitutes an "adequate" duration of antidepressant treatment?
45. Variability of response to lithium augmentation in refractory depression
46. Strategies for augmentation of SRI treatment: A survey of an academic psychopharmacology practice